(c) GenSight Biologics

GenSight receives approval for PIONEER trial to evaluate GS030, a combination Gene Therapy & Device treatment for patients with RP. May test AMD later.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK Medicines and Healthcare Regulatory Agency (MHRA) acceptance of the Company’s Clinical Trial Application (CTA) to initiate the PIONEER Phase I/II study of GS030 in patients with Retinitis Pigmentosa (RP).

Regenerating_mouse retinal ganglion cell

Visual Activity Regenerates Neural Connections Between Eye and Brain

A study in mice shows for the first time that high-contrast visual stimulation can help damaged retinal neurons regrow retinal ganglion cell axons. In combination with chemically induced neural stimulation, axons grew further than in strategies tried previously. Treated mice partially regained visual function. The study also demonstrates that adult regenerated central nervous system (CNS)

READ MORE…

Laser gene delivery system

A gene therapy platform for macular degeneration patients

Physics researchers at The University of Texas at Arlington have developed a new platform that uses ultrafast near-infrared lasers to deliver gene therapy to damaged areas of the retina to enable vision restoration in patients with photo-degenerative diseases such as macular degeneration. Samarenda Mohanty, assistant professor of physics and head of UTA’s Biophysics and Physiology

READ MORE…

Ocular gene therapy

Gene therapy for neovascular age-related macular degeneration safe at 1 year

Results from a single-center, phase 1, randomized controlled clinical trial show that ocular gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration was found to be safe and well tolerated. The study enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital in Nedlands, WA, Australia. Eligible

READ MORE…

blue-light-neuron

RetroSense Therapeutics Gets Approval for Clinical Trials in Retinitis Pigmentosa

RetroSense Therapeutics’ Investigational New Drug (IND) application for gene therapy based clinical trial for their product RST-001 has received clearance from the US Food and Drug Administration. RetroSense is developing RST-001 for the treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light),

READ MORE…